SCHEMBL8028979

SCHEMBL8028979

CCC(C(=O)O)N1Cc2sc(-c3ccc(-c4ccccc4)cc3)cc2S1(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
TP53 P04637 3/20 0.37
MMP1 P03956 2/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
IKBKB O14920 1/20 0.35
RAB9A P51151 5/20 0.35
NPC1 O15118 3/20 0.35
KDM4E B2RXH2 4/20 0.34
HPGD P15428 3/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34
ABCC1 P33527 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8025882 0.98 MMP1 (0.37) MAPTTP53MMP1MMP2MMP9
SCHEMBL13786795 0.98 MAPT (0.39) MAPTTP53MMP1MMP2MMP9
SCHEMBL8025974 0.94 MMP1 (0.35) MAPTTP53MMP1MMP2MMP9
SCHEMBL8027572 0.92 MMP1 (0.39) MAPTTP53MMP1MMP2MMP9
SCHEMBL13786684 0.91 ALDH1A1 (0.34) MAPTTP53RAB9ANPC1KDM4E
SCHEMBL13786858 0.91 TP53 (0.33) MAPTTP53MMP1
SCHEMBL8027320 0.91 S1PR1 (0.38) MAPTTP53MMP1MMP2MMP9
SCHEMBL13786691 0.91 MAPT (0.33) MAPTTP53MMP1MMP2MMP9
SCHEMBL13786731 0.91 GRM5 (0.39) MMP2MMP9
SCHEMBL8025862 0.91 MMP9 (0.43) MAPTTP53MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192154-A1 SULTAM DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2009-07-30 US disclosed
WO-2009084501-A1 SULTAM DERIVATIVE ASAHI KASEI PHARMA CORPORATION (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192154-A1 SULTAM DERIVATIVES SULT1A1, SULT2A1, ADAMTS1 MAPT 948/4885TP53 2835/4885MMP1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.